Amin Sobh,
RES AST PROF
Department:
MD-HEMATOLOGY/ONCOLOGY-ONCOL
Business Phone:
(352) 273-7832
Business Email:
asobh@ufl.edu
About Amin Sobh
I joined the Licht laboratory as a postdoctoral associate in May 2018 after I obtained a Ph.D. in comparative biochemistry from the University of California, Berkeley. My graduate research focused on the use of functional genomics tools, including genome-wide CRISPR screens, to study cellular mechanisms of toxicant susceptibility, as well as nutrient uptake. My current research involves identifying synthetic lethal targets associated with the histone lysine methyltransferase NSD2 overexpression in multiple myeloma (MM) and NSD2 gain-of-function point mutation in B-cell acute lymphoblastic leukemia (B-ALL). I am also investigating NSD2-driven mechanisms of chemotherapy resistance in MM and B-ALL using CRISPR-based genetic screens. The ultimate goal of this work is to identify therapeutic targets in blood malignancies with increased NSD2 activity, where the response to classical chemotherapeutic strategies is minimal.
Publications
Academic Articles
2024
Iron and cancer: overview of the evidence from population-based studies.
Frontiers in oncology.
14
[DOI] 10.3389/fonc.2024.1393195.
[PMID] 39246326.
2024
KDM6A Regulates Immune Response Genes in Multiple Myeloma.
bioRxiv : the preprint server for biology.
[DOI] 10.1101/2024.02.12.579179.
[PMID] 38405853.
2024
KDM6A regulates immune response genes in multiple myeloma.
Blood.
144(14):1508-1520
[DOI] 10.1182/blood.2024024518.
[PMID] 39046770.
2024
NSD2 drives t(4;14) myeloma cell dependence on adenylate kinase 2 by diverting one-carbon metabolism to the epigenome.
Blood.
144(3):283-295
[DOI] 10.1182/blood.2023022859.
[PMID] 38598835.
2024
Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells.
bioRxiv : the preprint server for biology.
[DOI] 10.1101/2024.02.24.581875.
[PMID] 38463958.
2023
Discovery of a Potent and Selective Targeted NSD2 Degrader for the Reduction of H3K36me2.
Journal of the American Chemical Society.
145(14):8176-8188
[DOI] 10.1021/jacs.3c01421.
[PMID] 36976643.
2023
Genome-wide CRISPR/Cas9 screen identifies etoposide response modulators associated with clinical outcomes in pediatric AML.
Blood advances.
7(9):1769-1783
[DOI] 10.1182/bloodadvances.2022007934.
[PMID] 36111891.
2023
Piperlongumine conjugates induce targeted protein degradation.
Cell chemical biology.
30(2):203-213.e17
[DOI] 10.1016/j.chembiol.2023.01.004.
[PMID] 36750097.
2022
Genetic impairment of succinate metabolism disrupts bioenergetic sensing in adrenal neuroendocrine cancer.
Cell reports.
40(7)
[DOI] 10.1016/j.celrep.2022.111218.
[PMID] 35977518.
2022
Genome-scale CRISPR screens identify host factors that promote human coronavirus infection.
Genome medicine.
14(1)
[DOI] 10.1186/s13073-022-01013-1.
[PMID] 35086559.
2022
Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL-Specific Degrader DT2216.
Molecular cancer therapeutics.
21(1):184-192
[DOI] 10.1158/1535-7163.MCT-21-0474.
[PMID] 34667112.
2021
Applying genome-wide CRISPR to identify known and novel genes and pathways that modulate formaldehyde toxicity.
Chemosphere.
269
[DOI] 10.1016/j.chemosphere.2020.128701.
[PMID] 33189395.
2021
CRISPR Screens in Toxicology Research: An Overview.
Current protocols.
1(5)
[DOI] 10.1002/cpz1.136.
[PMID] 34043288.
2021
Separation and Characterization of Endogenous Nucleosomes by Native Capillary Zone Electrophoresis-Top-Down Mass Spectrometry.
Analytical chemistry.
93(12):5151-5160
[DOI] 10.1021/acs.analchem.0c04975.
[PMID] 33749242.
2021
Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma.
Cancer research.
81(17):4581-4593
[DOI] 10.1158/0008-5472.CAN-20-3323.
[PMID] 34158378.
2020
Functional Pathway Identification With CRISPR/Cas9 Genome-wide Gene Disruption in Human Dopaminergic Neuronal Cells Following Chronic Treatment With Dieldrin.
Toxicological sciences : an official journal of the Society of Toxicology.
176(2):366-381
[DOI] 10.1093/toxsci/kfaa071.
[PMID] 32421776.
2020
Genetic screens reveal CCDC115 as a modulator of erythroid iron and heme trafficking.
American journal of hematology.
95(9):1085-1098
[DOI] 10.1002/ajh.25899.
[PMID] 32510613.
2019
Functional Profiling Identifies Determinants of Arsenic Trioxide Cellular Toxicity.
Toxicological sciences : an official journal of the Society of Toxicology.
169(1):108-121
[DOI] 10.1093/toxsci/kfz024.
[PMID] 30815697.
2019
Genome-Wide CRISPR Screening Identifies the Tumor Suppressor Candidate OVCA2 As a Determinant of Tolerance to Acetaldehyde.
Toxicological sciences : an official journal of the Society of Toxicology.
169(1):235-245
[DOI] 10.1093/toxsci/kfz037.
[PMID] 31059574.
2019
HOX Loci Focused CRISPR/sgRNA Library Screening Identifying Critical CTCF Boundaries.
Journal of visualized experiments : JoVE.
(145)
[DOI] 10.3791/59382.
[PMID] 30985763.
2018
CTCF boundary remodels chromatin domain and drives aberrant HOX gene transcription in acute myeloid leukemia.
Blood.
132(8):837-848
[DOI] 10.1182/blood-2017-11-814319.
[PMID] 29760161.
Grants
Jul 2022
ACTIVE
Adenylate Kinase 2-A Novel Therapeutic Target in Multiple Myeloma
Role: Other
Funding: LEUKEMIA & LYMPHOMA SOC
Oct 2021
– Sep 2024
Investigating the Role of Adenylate Kinase 2 in Multiple Myeloma
Role: Principal Investigator
Funding: LEUKEMIA & LYMPHOMA SOC
Jul 2019
– Dec 2021
Consequences and Vulnerabilities of NSD2 Overexpression in Multiple Myeloma
Role: Principal Investigator
Funding: AMER ASSO FOR CANCER RESEARCH
Contact Details
Phones:
- Business:
- (352) 273-7832
Emails:
- Business:
- asobh@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100278
GAINESVILLE FL 32610